Table 2.

Treatment and outcomes

	Imatinib response/dose/treatment duration	Imatinib PFS and TTP	Sunitinib response/dose/treatment duration/BSA	Sunitinib PFS and TTP	Overall follow up	Outcome	Adverse event/Toxicity during sunitinib treatment
Patient A	SD then PD; 400 mg OD then 300 mg OD; 8mo	PFS 17mo TTP 17mo	SD liver metastasis; 50 mg OD 4/2 schedule, then 37.5 mg OD; 73mo; 1.52m2	PFS 73mo TTP No progression	163mo	AWD on sunitinib since 2008	Hand and foot syndrome /TG 1 Arterial hypertension/TG 1 Skin rash/TG 2 Anaemia/TG 2 Diarrhoea/TG 2 Hypothyroidism/TG 2
Patient B	SD then PD; 400 mg OD; 9mo	PFS 8mo TTP 8mo	SD then PD; 37.5 mg OD then 50 mg OD 4/2 schedule; 7mo; 1.39m2	PFS 6mo TTP 6mo	159mo	AWD on regorafenib	Hypothyroidism/ TG 1 Diarrhoea/ TG 2 Skin rash/ TG 1
Patient C	SD then PD; 400 mg OD then 200 mg OD; 9mo	PFS 8mo TTP 8mo	SD then PD; 25 mg OD then 37.5 mg OD then 25 mg OD; 23 months; 1.28m2	PFS 6mo TTP 6mo	88mo	AWD on imatinib/doxorubicin	Cholecystitis /TG 3 Diarrhoea/TG 1
Patient D	PD; 400 mg OD; 12mo	PFS 12mo TTP 12mo	SD then PD; 50 mg OD 4/2 schedule then 37.5 mg OD; 24mo; 1.39m2	PFS 23mo TTP 23mo	260mo	AWD on treatment (nilotinib, then imatinib + doxorubicin, then imatinib 800 mg OD	Hypothyroidism/TG 3 Pyrosis/TG 1 Anaemia/TG 3 Thrombocytopenia/TG 2 Fatigue/TG 2 Amenorrhoea/TG 2 Discoloration of skin and hair/TG 2 Hand and foot syndrome/TG 2
Patient E	SD; 400 mg BID then 200 mg OD then 300 mg OD; 7mo	PFS 7mo TTP NA – intolerance (neutropenia, fatigue, joint pain)	PD; 25 mg OD 4/2 schedule (reduced due to prior intolerance of imatinib); 5mo; 1.51m2	PFS 5mo TTP 5mo	139mo	AWD, PD on nilotinib after sunitinib. Slow PD- asymptomatic, no treatment since 2011	Abdominal pain/TG 2 Bone pain/TG 2 Fatigue/TG 2 Patient elected to discontinue sunitinib due to above side effects, PD then documented
Patient F	NA	NA	PD; 50 mg OD 4/2 schedule; 1mo; 1.50m2	PFS 1mo TTP 1mo	25mo	DOD, after sunitinib also failed trametinib, regorafenib, a phase 1 clinical trial and pazopanib	Fatigue/TG 1 Thrombocytopenia/TG 1
Patient G	SD then PD; 400 mg OD; 14mo	PFS 14mo TTP 14mo	SD then PD; 37.5 mg OD then discontinued for 3mo for toxicity then restarted 12.5 mg OD increasing to 25 mg OD; 17mo; 1.65m2	PFS 17mo TTP 17mo	76mo	AWD, no treatment since sunitinib and subsequent SD under observation from 2012	Fatigue/TG 1 Oedema/TG 2 Epistaxis/TG 1 Headaches/TG 1
Patient H	SD then PD; 400 mg OD then 800 mg OD: 49mo	PFS 9mo TTP 9mo	SD for duration but initial minor response; Initial dose 50 mg OD, lowest dose 12.5 mg OD; 17mo; 1.60m2	PFS 5mo TTP 5mo	173mo	AWD on imatinib	Fatigue/TG 3 Mucositis/TG 3 Diarrhoea/TG 3
Patient I	SD then PD; 400 mg OD; 1mo	PFS 2mo TTP 2mo	SD then PD then SDa; 50 mg OD then 37.5 mg OD; >42mo (RFA during treatment for liver metastases); b1.68m2	PFS 28mo TTP 28mo	86mo	AWD on sunitinib	Mucositis /TG 2 Diarrhoea/TG 2 Hypertension/TG 2

^aPD liver lesion treated with RFA; ^bLast recorded July 2012

AWD = alive with disease; BSA = Body surface area at start of sunitinib treatment (a, last record; b, during therapy); DOD = dead of disease; OD = once daily; mo = months; NA = not applicable; PD = progressive disease; PFS = progression-free survival; RFA = Radiofrequency Ablation; SD = stable disease; TG = toxicity grade; TTP = time to progression; 4/2 schedule = 4 weeks of daily treatment and 2 weeks no treatment